All In Biotech

Drug Trial Radar · NCT00127530

Study of Oral Fampridine-SR in Multiple Sclerosis

Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

May 2005

Primary completion

Jun 2006

Study completion Sep 2006

Sponsor

Lead sponsor
Acorda TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.

Conditions

  • Multiple Sclerosis

Interventions

  • Fampridine-SRDrug

    Tablets, 10 mg, twice daily, 14 weeks

  • PlaceboDrug

    sugar pill, twice a day (b.i.d.)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk)Time frame: Days 14, 42, 70 and 98 of treatment, corresponding to the four on-drug visits during double-blind treatment period.

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • USC, Keck School of Medicine

    Los Angeles, California

  • UC Davis

    Sacramento, California

  • University of Colorado Health Sciences Center

    Denver, Colorado

  • Multiple Sclerosis Treatment Center

    Derby, Connecticut

  • Shepard Center

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Indiana University MS Center

    Indianapolis, Indiana

  • Maryland Center for MS

    Baltimore, Maryland

  • Wayne State University, Department of Neurology

    Detroit, Michigan

  • The Schapiro Center for MS

    Golden Valley, Minnesota

  • Washington University SOM

    St Louis, Missouri

  • Gimbel MS Center at Holy Name Hospital

    Teaneck, New Jersey

  • University of Mexico, MIND Imaging Center

    Albuquerque, New Mexico

  • Maimonides Medical Center

    Brooklyn, New York

  • Corinne Goldsmith Dickinson Center for MS

    New York, New York

  • University of Rochester

    Rochester, New York

  • SUNY - Stony Brook

    Stony Brook, New York

  • Carolinas Healthcare System

    Charlotte, North Carolina

  • Cleveland Clinical Foundation

    Cleveland, Ohio

  • Ohio State University MS Center

    Columbus, Ohio

  • Oregon Health & Science University, MS Center of Oregon, UHS-42

    Portland, Oregon

  • Thomas Jefferson University Physicians

    Philadelphia, Pennsylvania

  • Allegheny General Hospital, Allegheny Neurological Associates

    Pittsburgh, Pennsylvania

  • University of Texas - Houston

    Houston, Texas

  • Neurological Research Center, Inc.

    Bennington, Vermont

  • Fletcher Allen Health Care

    Burlington, Vermont

  • MS Hub Medical Group

    Seattle, Washington

  • University of Washington, MS Research Center

    Seattle, Washington

  • Foothills Medical Center

    Calgary, Alberta, Canada

  • University of British Columbia, Vancouver Coastal Health Research Institute

    Vancouver, British Columbia, Canada

  • QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site

    Halifax, Nova Scotia, Canada

  • Ottawa Hospital General Campus

    Ottawa, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.